Scenario analysis when conducting budget impact analyses for rare diseases

Area of Science:

• Health Economics
• Pharmacoeconomics
• Rare Disease Therapeutics

Background:

• Pharmacoeconomic analyses, particularly budget impact analyses (BIAs), are crucial for assessing the financial implications of pharmacotherapeutic interventions.
• Existing BIA methodology guidelines in the United States primarily focus on common diseases, leaving a gap for rare or ultrarare disease states.
• Understanding the economic impact of treatments for rare diseases is essential for healthcare resource allocation and policy decisions.

Purpose of the Study:

• To propose a novel scenario analysis approach for budget impact assessments of pharmacotherapeutic interventions in rare diseases.
• To adapt existing budget impact analysis methodologies for the unique challenges presented by rare or ultrarare disease states.
• To provide a framework for estimating the financial implications of treating rare disease patients within varying health plan contexts.

Main Methods:

• A scenario analysis was proposed, involving the variation of health plan sizes.
• The methodology focuses on estimating the potential budget impact if a single member within a health plan receives treatment for a rare disease.
• An illustrative example is presented to demonstrate the application and rationale of the proposed scenario analysis.

Main Results:

• The proposed scenario analysis provides a flexible method to estimate the budget impact of rare disease treatments across different healthcare settings.
• Varying health plan sizes allows for a nuanced understanding of potential financial implications, even with small patient populations.
• The illustrative example demonstrates the practical application of the method in a real-world context.

Conclusions:

• The scenario analysis offers a practical and adaptable approach to conducting budget impact analyses for rare disease pharmacotherapies.
• This method addresses the limitations of current guidelines by providing specific guidance for ultrarare conditions.
• The findings support better financial planning and decision-making for integrating novel therapies for rare diseases into healthcare systems.